Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Cross-over Study to Assess the Safety, Tolerability and Efficacy of Oral Ketamine for Patients With Rett Syndrome

To see complete record on, please visit this link

Id: NCT03633058

Organisation Name: Rett Syndrome Research Trust

Overal Status: Completed

Start Date: March 12, 2019

Last Update: April 22, 2022

Lead Sponsor: Rett Syndrome Research Trust

Brief Summary: This 2 cohort, sequential, ascending dose study will assess the safety, tolerability and efficacy of oral ketamine dosed in a single 5-day BID regimen in addition to placebo, in a 4-week cross-over design in patients with Rett Syndrome. Approximately 12 patients per cohort are anticipated to participate for approximately 8-10 weeks at approximately 7 US study centers.

  • Rett Syndrome

Total execution time in seconds: 0.25890898704529